BioNexus Gene Lab Corp. Income Taxes Receivable, Current
BioNexus Gene Lab Corp. (BGLC) had Income Taxes Receivable, Current of $61.13 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › and Others › Nontrade Receivables
us-gaap:IncomeTaxesReceivable · last filed 2026-08-14
- 2026-06-30: Income Taxes Receivable, Current $61.13K.
- 2026-03-31: Income Taxes Receivable, Current $61.61K.
- 2025-12-31: Income Taxes Receivable, Current $61.38K.
- 2025-09-30: Income Taxes Receivable, Current $103.64K.
| Period end | Income Taxes Receivable, Current |
|---|---|
| 2026-06-30 | $61.13K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $61.61K 10-Q · filed 2026-05-15 |
| 2025-12-31 | $61.38K 10-Q · filed 2026-08-14 |
| 2025-09-30 | $103.64K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $101.47K 10-Q · filed 2025-08-18 |
| 2025-03-31 | $89.94K 10-Q · filed 2025-05-15 |
| 2024-12-31 | $84.17K 10-K · filed 2026-04-14 |
| 2024-09-30 | $22.13K 10-Q · filed 2024-11-15 |
| 2024-06-30 | $7.04K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $50.44K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $57.59K 10-K · filed 2025-04-15 |
| 2023-09-30 | $3.84K 10-Q/A · filed 2024-03-26 |
| 2023-06-30 | $59.00K 10-Q · filed 2023-08-16 |
| 2023-03-31 | $27.82K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $31.55K 10-K · filed 2024-04-16 |
| 2022-09-30 | $52.75K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $3.39K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $1.77K 10-Q · filed 2022-05-16 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-31 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-15 |
| 2021-06-30 | $2.73K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $2.62K 10-Q · filed 2021-05-18 |
| 2020-12-31 | $2.19K 10-K · filed 2022-04-06 |
| 2020-09-30 | $0.00 10-Q/A · filed 2020-11-09 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-11 |
| 2020-03-31 | $3.04K 10-Q · filed 2020-05-08 |
| 2019-12-31 | $2.86K 10-K · filed 2021-03-30 |
| 2019-09-30 | $622.00 10-Q · filed 2019-11-14 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |